About: Decoding the enigma of antiviral crisis: Does one target molecule regulate all?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Decoding the enigma of antiviral crisis: Does one target molecule regulate all? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Decoding the enigma of antiviral crisis: Does one target molecule regulate all?
Creator	Mahmud-Al-Rafat, Abdullah Majumder, Apurba Billah, Morsaline Didarul Islam, K Hasan, A Rahman, K Taylor-Robinson, Andrew
Source	Elsevier; Medline; PMC
abstract	Abstract Disease fatality associated with Ebola, SARS-CoV and dengue infections in humans is attributed to a cytokine storm that is triggered by excessive pro-inflammatory responses. Interleukin (IL)-6 acts as a mediator between pro- and anti-inflammatory reactivity by initiating trans- and classical-signaling, respectively. Hence, IL-6 is assumed to provide a target for a broad range of antiviral agents. Available immunosuppressive antivirals are directed to control an often exaggerated pro-inflammatory response that gives rise to complex clinical conditions such as lymphocytopenia. It is known that IL-6, via its soluble receptor (sIL-6R), initiates a pro-inflammatory response while an anti-inflammatory response is triggered by the membrane-bound IL-6 receptor (IL-6R). Future antivirals should thus aim to target the mechanism that regulates switching between IL-6 trans- and classical-signaling. In this review, we propose that the tumour necrosis factor-α converting enzyme ADAM-17 could be the master molecule involved in regulating IL-6 class switching and through this in controlling pro- and anti-inflammatory responses to viral antigenic stimuli. Therefore, ADAM-17 should be considered as a potential target molecule for novel antiviral drug discovery that would regulate host reactivity to infection and thereby limit or prevent fatal outcomes.
has issue date	2019-03-31(xsd:dateTime)
bibo:doi	10.1016/j.cyto.2018.12.008
bibo:pmid	30616034
has license	els-covid
sha1sum (hex)	c1b06425240046eb4848fada16e65183b45fdc15
schema:url	https://doi.org/10.1016/j.cyto.2018.12.008
resource representing a document's title	Decoding the enigma of antiviral crisis: Does one target molecule regulate all?
has PubMed Central identifier	PMC7129598
has PubMed identifier	30616034
schema:publication	Cytokine
resource representing a document's body	covid:c1b06425240046eb4848fada16e65183b45fdc15#body_text
is schema:about of	named entity 'TARGET' named entity 'DOES' named entity 'ANTIVIRAL' named entity 'REGULATE' named entity 'CRISIS' named entity 'ENIGMA' named entity 'MOLECULE' named entity 'DECODING' named entity 'TNFSF10' named entity 'circulatory failure' named entity 'Ebola' named entity 'antiviral' named entity 'cytokine' named entity 'Clinical laboratory testing' named entity 'clinical features' named entity 'immune cells' named entity 'lymphocytes' named entity 'broad spectrum' named entity 'caspases' named entity 'infection' named entity 'apoptotic' named entity 'Apoptosis' named entity 'apoptosis' named entity 'chemokines' named entity 'MCP-1' named entity 'antiviral' named entity 'phase II trial' named entity 'necrosis' named entity 'IL-6R' named entity 'antiviral' named entity 'FasL' named entity 'IFN-γ' named entity 'type 2' named entity 'antiviral' named entity 'liver' named entity 'IL-6R' named entity 'Histological examination' named entity 'interferon' named entity 'anti-inflammatory' named entity 'IL-10' named entity 'negative feedback loop' named entity 'lymphocytes' named entity 'IL-6' named entity 'homeostasis' named entity 'nausea' named entity 'IL-6' named entity 'Plasma' named entity 'Glaxo SmithKline' named entity 'pro-inflammatory cytokine' named entity 'pro-inflammatory cytokines' named entity 'cytokine storm' named entity 'target molecule' named entity 'fever' named entity 'macrophages' named entity 'NFKB1' named entity 'apoptotic' named entity 'chemokines' named entity 'IL-6R' named entity 'upregulate' named entity 'cytokine storm' named entity 'infection' named entity 'innate immunity' named entity 'infection' named entity 'NR3C1' named entity 'lipid' named entity 'virus' named entity 'emergency treatment' named entity 'receptor' named entity 'Ebola' named entity 'DHF' named entity 'vaccines' named entity 'SARS' named entity 'inflammatory responses' named entity 'cidofovir' named entity 'IL-6'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software